XTLB vs ZURA

XTL Biopharmaceuticals Ltd. vs Zura Bio Limited — Valuation Comparison 2026

XTLB

Biotechnology
XTL Biopharmaceuticals Ltd.
Quality
1.7
out of 10
Value Trap
Price
$2.46
Last close
Models
6/13
Active
VS

ZURA

Biotechnology
Zura Bio Limited
Quality
4.9
out of 10
Value Trap
12
SAFE
Price
$4.20
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType XTLB Fair ValueXTLB Upside ZURA Fair ValueZURA Upside
Bayesian DCF Intrinsic $0.65 -73.5% $2.42 -42.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.60 -38.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $0.72 -71.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for XTLB vs ZURA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XTLB vs ZURA — Which Stock Is More Undervalued?

ZURA scores higher with a 4.9/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XTL Biopharmaceuticals Ltd. (XTLB) and Zura Bio Limited (ZURA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XTLB currently trades at $2.46 with a QOC of 1.7/10, while ZURA trades at $4.20 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).